Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): A multicentre, open-label, randomised controlled trial

The Lancet

Volumn 385, Issue 9981, 2015, Pages 1957-1965

  Azizi, Michel ^a,b,c   Sapoval, Marc ^a,b   Gosse, Philippe ^g   Monge, Matthieu ^b   Bobrie, Guillaume ^b   Delsart, Pascal ^d   Midulla, Marco ^d   Mounier Véhier, Claire ^d   Courand, Pierre Yves ^e   Lantelme, Pierre ^e,f   Denolle, Thierry ⁱ   Dourmap Collas, Caroline ^j   Trillaud, Hervé ^h   Pereira, Helena ^c   Plouin, Pierre François ^a,b   Chatellier, Gilles ^a,c  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c INSERM   (France)

^d LILLE UNIVERSITY HOSPITAL   (France)

^e CROIX ROUSSE HOSPITAL   (France)

^f University Lyon 1   (France)

^g BORDEAUX UNIVERSITY HOSPITAL   (France)

^h HÔPITAL SAINT ANDRÉ   (France)

ⁱ Arthur Gardiner Hospital   (France)

^j RENNES UNIVERSITY HOSPITAL   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANTIHYPERTENSIVE AGENT; BISOPROLOL; INDAPAMIDE; IRBESARTAN; PRAZOSIN; RAMIPRIL; RILMENIDINE; SPIRONOLACTONE;

ADULT; AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE MONITORING; CONTROLLED STUDY; FEMALE; GLOMERULUS FILTRATION RATE; GROIN HEMATOMA; HUMAN; INCIDENCE; INTENTION TO TREAT ANALYSIS; KIDNEY DENERVATION; LOW BACK PAIN; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; MEDICATION COMPLIANCE; MULTICENTER STUDY; OPEN STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RESISTANT HYPERTENSION; SYSTOLIC BLOOD PRESSURE; TERTIARY CARE CENTER; TREATMENT DURATION; ADOLESCENT; CATHETER ABLATION; CLINICAL TRIAL; COMPARATIVE STUDY; DENERVATION; DRUG COMBINATION; DRUG RESISTANCE; HYPERTENSION; INNERVATION; KIDNEY ARTERY; MIDDLE AGED; PROCEDURES; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIHYPERTENSIVE AGENTS; CATHETER ABLATION; DENERVATION; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERTENSION; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL ARTERY; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84929606094     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(14)61942-5     Document Type: Article

References (30)

1. M Esler Renal denervation for hypertension: observations and predictions of a founder Eur Heart J 35 2014 1178 1185
2. H Krum, M Schlaich, R Whitbourn et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study Lancet 373 2009 1275 1281
3. MD Esler, H Krum, PA Sobotka, MP Schlaich, RE Schmieder, M Böhm the Symplicity HTN-2 Investigators Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial Lancet 376 2010 1903 1909
4. RE Schmieder, J Redon, G Grassi et al. ESH position paper: renal denervation - an interventional therapy of resistant hypertension J Hypertens 30 2012 837 841
5. F Mahfoud, TF Lüscher, B Andersson the European Society of Cardiology Expert consensus document from the European Society of Cardiology on catheter-based renal denervation Eur Heart J 34 2013 2149 2157
6. G Mancia, R Fagard, K Narkiewicz et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) Eur Heart J 34 2013 2159 2219
7. M Azizi, O Steichen, M Frank, G Bobrie, PF Plouin, M Sapoval Catheter-based radiofrequency renal-nerve ablation in patients with resistant hypertension Eur J Vasc Endovasc Surg 43 2012 293 299
8. A Persu, J Renkin, L Thijs, JA Staessen Renal denervation: ultima ratio or standard in treatment-resistant hypertension Hypertension 60 2012 596 606
9. T Krause, K Lovibond, M Caulfield, T McCormack, B Williams the Guideline Development Group Management of hypertension: summary of NICE guidance BMJ 343 2011 d4891
10. GS Stergiou, MG Myers, JL Reid et al. Setting-up a blood pressure and vascular protection clinic: requirements of the European Society of Hypertension J Hypertens 28 2010 1780 1781
11. T Okada, O Pellerin, S Savard et al. Eligibility for renal denervation: anatomical classification and results in essential resistant hypertension Cardiovasc Intervent Radiol 38 2015 79 87
12. V Korb-Savoldelli, F Gillaizeau, J Pouchot et al. Validation of a French version of the 8-item Morisky medication adherence scale in hypertensive adults J Clin Hypertens (Greenwich) 14 2012 429 434
13. E O'Brien, R Asmar, L Beilin the European Society of Hypertension Working Group on Blood Pressure Monitoring Practice guidelines of the European Society of Hypertension for clinic, ambulatory and self blood pressure measurement J Hypertens 23 2005 697 701
14. G Bobrie, M Frank, M Azizi et al. Sequential nephron blockade versus sequential renin-angiotensin system blockade in resistant hypertension: a prospective, randomized, open blinded endpoint study J Hypertens 30 2012 1656 1664
15. SB Pancholy, GP Shantha, TM Patel, PA Sobotka, DE Kandzari Meta-analysis of the effect of renal denervation on blood pressure and pulse pressure in patients with resistant systemic hypertension Am J Cardiol 114 2014 856 861
16. JA Staessen, JG Wang, L Thijs Cardiovascular protection and blood pressure reduction: a meta-analysis Lancet 358 2001 1305 1315
17. MD Esler, M Böhm, H Sievert et al. Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension: 36 month results from the SYMPLICITY HTN-2 randomized clinical trial Eur Heart J 35 2014 1752 1759
18. H Krum, MP Schlaich, PA Sobotka et al. Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study Lancet 383 2014 622 629
19. DL Bhatt, DE Kandzari, WW O'Neill the SYMPLICITY HTN-3 Investigators A controlled trial of renal denervation for resistant hypertension N Engl J Med 370 2014 1393 1401
20. MD Esler, H Krum, M Schlaich, RE Schmieder, M Böhm, PA Sobotka the Symplicity HTN-2 Investigators Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the Symplicity HTN-2 randomized, controlled trial Circulation 126 2012 2976 2982
21. A Persu, Y Jin, M Azizi the European Network COordinating research on Renal Denervation (ENCOReD) Blood pressure changes after renal denervation at 10 European expert centers J Hum Hypertens 28 2014 150 156
22. CS Zuern, C Eick, KD Rizas et al. Impaired cardiac baroreflex sensitivity predicts response to renal sympathetic denervation in patients with resistant hypertension J Am Coll Cardiol 62 2013 2124 2130
23. SI Al Raisi, J Pouliopoulos, MT Barry et al. Evaluation of lesion and thermodynamic characteristics of Symplicity and EnligHTN renal denervation systems in a phantom renal artery model EuroIntervention 10 2014 277 284
24. M Burnier, G Wuerzner, H Struijker-Boudier, J Urquhart Measuring, analyzing, and managing drug adherence in resistant hypertension Hypertension 62 2013 218 225
25. GL Bakris, RR Townsend, M Liu the SYMPLICITY HTN-3 Investigators Impact of renal denervation on 24-hour ambulatory blood pressure: results from SYMPLICITY HTN-3 J Am Coll Cardiol 64 2014 1071 1078
26. A Persu, Y Jin, M Baelen the European Network Coordinating research on REnal Denervation Consortium Eligibility for renal denervation: experience at 11 European expert centers Hypertension 63 2014 1319 1325
27. MI Davis, KB Filion, D Zhang et al. Effectiveness of renal denervation therapy for resistant hypertension: a systematic review and meta-analysis J Am Coll Cardiol 62 2013 231 241
28. SG Worthley, CP Tsioufis, MI Worthley et al. Safety and efficacy of a multi-electrode renal sympathetic denervation system in resistant hypertension: the EnligHTN I trial Eur Heart J 34 2013 2132 2140
29. DH Smith, JM Neutel, Y Lacourcière, J Kempthorne-Rawson Prospective, randomized, open-label, blinded-endpoint (PROBE) designed trials yield the same results as double-blind, placebo-controlled trials with respect to ABPM measurements J Hypertens 21 2003 1291 1298
30. R Macklin The ethical problems with sham surgery in clinical research N Engl J Med 341 1999 992 996